A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT2527, a CDK9 Inhibitor in Adult Patients With Advanced Solid Tumors

Jason T. Henry, Douglas Orr, Atrayee Basu-Mallick, Alex Spira, Christine Lihou, William Sun, Neelesh Sharma, Peggy Scherle, Rachel Chiaverelli, Manish R. Patel